Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 9 ... Diseases. This phase 2 study was of telaprevir compared to a combination therapy of peginterferon alfa-2a and ribavirin. It intended to measure the 6 month and also 1-year durability of ...
2009 NOV 2 ... ACHIEVE 2/3, showed that ZALBIN met its primary endpoint of non-inferiority to Pegasys (peginterferon alfa-2a). With half the injections, ZALBIN achieved a rate of sustained virologic response ...
2009 NOV 16 ... Disease, Liver Disease, Marketing and Licensing Agreements, Nausea, Neurology, Pegasys, Peginterferon Alfa 2a, Pharmaceuticals, Pharmacokinetics, Protease Inhibitor, Protease Inhibitors, ... twice daily) or every eight hours (q8h; three times daily) combined with either peg-IFN-alfa-2a (PEGASYS®) or peg-IFN-alfa-2b (PEGINTRON®) and ribavirin (RBV), for 12 weeks ...
2009 NOV 1 ... genotype-1 patients enrolled in two phase III studies (NV15801/NV15942) randomized to peginterferon alfa-2a (40KDa) 180 mu g/week plus ribavirin 1000/1200 mg/day for 48-weeks, we investigated ...
2009 NOV 16 ... to a study from Melbourne, Australia, "This study tested the hypothesis that high-dose peginterferon alfa-2a (PEG-IFN alpha-2a) for the first 12 weeks would increase early and sustained virological ...
